Literature DB >> 11886464

Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients.

S Royal1, W Schramm, E Berntorp, P Giangrande, A Gringeri, C Ludlam, B Kroner, T Szucs.   

Abstract

The European Study on the Clinical Outcomes and Resource Utilization associated with Haemophilia Care was designed to compare various health outcomes associated with on-demand and prophylactic factor substitution methods in European haemophilia patients. While the primary objective of this research is to conduct an economic analysis, an important component of this study is to evaluate quality-of-life differences that may exist between patients who utilize these two styles of therapy. Quality-of-life research has emerged as a primary measure of health outcomes because it allows the augmentation of traditional clinical indicators of health with data gathered from the patient's perspective. A total of 1033 haemophilia patients from 16 European haemophilia treatment centres were enrolled in this study. The SF-36, a multidimensional quality-of-life instrument, was administered to all participants. This instrument measures eight health-related quality-of-life dimensions: physical functioning, physical role limitations, bodily pain, general health, vitality, social functioning, emotional role limitations, and mental health. All haemophilia subjects enrolled in the study scored significantly lower than the population normative means in the three physical dimensions and in the general health dimension. HIV-negative haemophiliac subjects differed significantly by factor substitution type in a multivariate analysis examining all eight health dimensions. Univariate analyses testing each dimension separately indicated that patients treated prophylactically reported significantly less bodily pain, better general health, and scored significantly higher in the physical functioning, mental health, and social functioning dimensions. While these results suggest that health-related quality-of-life may be better for haemophilia patients treated prophylactically, future prospective studies that gather periodic quality-of-life data over time should be conducted.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11886464     DOI: 10.1046/j.1365-2516.2002.00581.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  22 in total

1.  6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

Review 2.  The history and evolution of the clinical effectiveness of haemophilia type a treatment: a systematic review.

Authors:  Hector E Castro; María Fernanda Briceño; Claudia P Casas; Juan David Rueda
Journal:  Indian J Hematol Blood Transfus       Date:  2012-11-04       Impact factor: 0.900

Review 3.  Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis.

Authors:  Scott D Grosse; Shraddha S Chaugule; Joel W Hay
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015-01-14       Impact factor: 2.217

Review 4.  Preventing perioperative bleeding in patients with inherited bleeding disorders.

Authors:  Colin Watterson; Nicholas Beacher
Journal:  Evid Based Dent       Date:  2017-03

5.  Social/economic costs and quality of life in patients with haemophilia in Europe.

Authors:  Marianna Cavazza; Yllka Kodra; Patrizio Armeni; Marta De Santis; Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Domenica Taruscio; Arrigo Schieppati; Georgi Iskrov; László Gulácsi; Johann Matthias Graf von der Schulenburg; Panos Kanavos; Karine Chevreul; Ulf Persson; Giovanni Fattore
Journal:  Eur J Health Econ       Date:  2016-04-05

6.  A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management.

Authors:  L A Valentino; V Mamonov; A Hellmann; D V Quon; A Chybicka; P Schroth; L Patrone; W-Y Wong
Journal:  J Thromb Haemost       Date:  2012-03       Impact factor: 5.824

7.  Physiotherapy treatment in patients with hemophilia and chronic ankle arthropathy: a systematic review.

Authors:  Rubén Cuesta-Barriuso; Antonia Gómez-Conesa; José Antonio López-Pina
Journal:  Rehabil Res Pract       Date:  2013-08-12

8.  Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A.

Authors:  Steven Pipe
Journal:  Biologics       Date:  2009-07-13

Review 9.  Personalised Prophylaxis in a Child with Haemophilia A and Type 1 Diabetes.

Authors:  Maria Sol Cruz; Josefina Santillan; Julieta Lesser; Juan Pablo Ortiz; Laura Forzani
Journal:  Clin Pract       Date:  2021-05-08

10.  Barriers and perceived limitations to early treatment of hemophilia.

Authors:  Kapil Saxena
Journal:  J Blood Med       Date:  2013-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.